Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The number of studies reporting antimicrobial resistance (AMR) data has increased in Africa, South and South East Asia according to new research in the International Journal of Infectious Diseases.

Two researchers looking at data

Authors of the paper, Antimicrobial resistance patterns in bacteria causing febrile illness in Africa, South Asia and Southeast Asia: A systematic review of published aetiological studies from 1980-2015, have recommended three measures to improve surveillance of AMR nationally and regionally. These include strengthening laboratory capacity, standardised testing and reporting of antimicrobial susceptibility testing results.

AMR is a serious threat to global public health and threatens the treatment of infections caused by bacteria, viruses, parasites and fungi. Over time, these microorganisms change and no longer respond to medicines resulting in treatment failure, a risk of disease spread, more severe illness and ultimately death.

Researchers used the IDDO non-malarial febrile illness (NMFI) map to conduct a systematic review to characterise AMR patterns for bacterial causes of febrile illness in Africa and Asia. A total of 371 unique articles over a period of 30-years included the target pathogen-drug combinations.

The main findings were:

  • An increase in the number of studies reporting antimicrobial resistance data over time and a high number of studies reporting 3rd generation cephalosporin resistance in Asia for Escherichia coli and Klebsiella pneumoniae and in Africa for K. pneumoniae. 
  • An increase in the pooled proportion of resistance to fluoroquinolones in Salmonella enterica over time in both regions. 
  • Overall, there was a general paucity of data and a lack of standardisation and data quality assurance.
  • Strengthening of laboratory capacity and standardised testing and reporting of antimicrobial susceptibility testing results is required to improve surveillance of AMR both nationally and regionally. 

The full story is available on the IDDO website

Similar stories

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

OUCRU’s Photographer In Residence Featured In The Lancet’s Highlights 2022

Photographs have the power to inform and engage viewers. Earlier this year, The Lancet invited submissions for Highlights, the publication’s annual photography competition. Highlights 2022 featured 14 winning photographs telling stories from a wide variety of health-related topics that captured the world’s attention in 2022. One of the powerful images selected was from Pearl Gan, OUCRU’s Photographer in Residence.

COPCOV investigators meet, and prepare to submit for publication

On 15-16 Dec, COPCOV investigators from around the world met in Bangkok to review study results and plan next steps. Led by co-PIs Prof Sir Nick White and Dr Will Schilling, and funded by the Wellcome Trust, the MORU-led COPCOV ( Chloroquine prevention of coronavirus disease (COVID-19) in the healthcare setting) is the world’s largest multinational trial of COVID-19 prevention.

Expert Comment: Biotechnology allows us to make unprecedented interventions for conservation

In the wake of high-profile reports on the devastating toll human activity has had on global biodiversity, nations are expected to adopt the Convention on Biodiversity post-2020 framework that outlines measures to ensure humans live in harmony with nature.

Are we getting tafenoquine dosing right?

Researchers analysing clinical trial data for the new antimalarial drug tafenoquine find that higher doses are needed to cure reliably vivax malaria infection.

New SMRU building opened in Thailand to provide health care to marginalized populations

The inauguration of a new joint Shoklo Malaria Research Unit (SMRU) and Borderland Health Foundation (BHF) Building took place in Mae Ramat, Thailand, this week.